Last reviewed · How we verify
Azzalure or Dysport
Azzalure is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, paralyzing facial muscles and reducing wrinkles.
Azzalure is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, paralyzing facial muscles and reducing wrinkles. Used for Moderate to severe glabellar lines (frown lines between eyebrows), Moderate to severe lateral canthal lines (crow's feet), Forehead lines.
At a glance
| Generic name | Azzalure or Dysport |
|---|---|
| Also known as | Botulinum toxin |
| Sponsor | Galderma R&D |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (synaptosome-associated protein) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin type A binds to SNARE proteins on presynaptic nerve terminals and cleaves them, preventing the release of acetylcholine. This leads to temporary paralysis of targeted facial muscles, smoothing dynamic wrinkles and expression lines. The effect is reversible and typically lasts 3–4 months.
Approved indications
- Moderate to severe glabellar lines (frown lines between eyebrows)
- Moderate to severe lateral canthal lines (crow's feet)
- Forehead lines
Common side effects
- Headache
- Injection site pain or bruising
- Eyelid ptosis
- Brow ptosis
- Facial asymmetry
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
- Dual-Site Botulinum Toxin Type A Injection for Lifelong Premature Ejaculation (NA)
- Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy (PHASE2, PHASE3)
- Silencing Neuroma Pain-Botulinum Toxin Versus Local Anesthetic Injection (NA)
- A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azzalure or Dysport CI brief — competitive landscape report
- Azzalure or Dysport updates RSS · CI watch RSS
- Galderma R&D portfolio CI